BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8898435)

  • 1. Economic evaluation in gastrointestinal disease.
    Jönsson B; Karlsson G
    Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
    Jönsson B
    Scand J Gastroenterol Suppl; 1996; 215():90-5. PubMed ID: 8722390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
    Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
    Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
    Craig AM; Davey P; Malek M; Murray F
    Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
    Duggan AE; Tolley K; Hawkey CJ; Logan RF
    BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
    O'Brien B; Goeree R; Mohamed AH; Hunt R
    Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
    Unge P; Jönsson B; Stålhammar NO
    Pharmacoeconomics; 1995 Nov; 8(5):410-27. PubMed ID: 10160075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
    Frampton JE; McTavish D
    Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
    Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
    Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
    Adamek RJ; Behrendt J; Wenzel C
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
    Wilde MI; McTavish D
    Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study.
    Saberi-Firoozi M; Massarrat S; Zare S; Fattahi M; Javan A; Etaati H; Dehbashi N
    Am J Gastroenterol; 1995 Sep; 90(9):1419-23. PubMed ID: 7661161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer.
    O'Brien B; Goeree R; Hunt R; Wilkinson J; Levine M; William A
    Can J Gastroenterol; 1997; 11(4):323-31. PubMed ID: 9218858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of new medical technology.
    Jönsson B
    Scand J Gastroenterol Suppl; 1994; 201():87-90. PubMed ID: 8047831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of omeprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the healing of duodenal ulcer: comparison with a historical control.
    Schütze K; Hentschel E; Hirschl AM
    Hepatogastroenterology; 1999; 46(28):2358-62. PubMed ID: 10521998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.